Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase

Chemico-Biological Interactions

Volumn 191, Issue 1-3, 2011, Pages 66-74

  Skarka, Adam ^a   Škarydová, Lucie ^a   Štambergová, Hana ^a   Wsól, Vladimír ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Anthracyclines; Carbonyl reduction; Daunorubicin; Doxorubicin; Enzyme kinetics; Idarubicin; Microsomal fraction; Microsomes; Purification

Indexed keywords

ADRIAMYCINONE; ANTHRACYCLINE ANTIBIOTIC AGENT; CARBON 13; CARBONYL REDUCTASE; DAUNOMYCINONE; DAUNORUBICIN; DAUNORUBICINOL; DAUNORUBICINOLONE; DOXORUBICIN; DOXORUBICINOL; DOXORUBICINOLONE; HYDROLASE; IDARUBICIN; IDARUBICINOLONE; IDARUBICINONE; UNCLASSIFIED DRUG;

BINDING SITE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME PURIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROLYSIS; LIVER CYTOSOL; LIVER MICROSOME METABOLISM; MICROSOME;

ALCOHOL OXIDOREDUCTASES; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CELL MEMBRANE; HUMANS; MICROSOMES, LIVER; SUBSTRATE SPECIFICITY;

FORMICIDAE;

EID: 79957572955     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.12.016     Document Type: Conference Paper

References (40)

1. M.J. Rosemond, J.S. Walsh, Human carbonyl reduction pathways and a strategy for their study in vitro, Drug Metab. Rev. 36 (2004) 335-361.
2. F. Hoffmann, E. Maser, Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily, Drug Metab. Rev. 39 (2007) 87-144.
3. O.A. Barski, S.M. Tipparaju, A. Bhatnagar, The aldo-keto reductase superfamily and its role in drug metabolism and detoxification, Drug Metab. Rev. 40 (2008) 553-624.
4. E. Maser, U.C. Oppermann, Role of type-1 11beta-hydroxysteroid dehydrogenase in detoxification processes, Eur. J. Biochem. 249 (1997) 365-369.
5. E. Maser, V. Wsol, H.J. Martin, 11Beta-hydroxysteroid dehydrogenase type 1: purification from human liver and characterization as carbonyl reductase of xenobiotics, Mol. Cell. Endocrinol. 248 (2006) 34-37.
6. J.E. Bray, B.D. Marsden, U. Oppermann, The human short-chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics summary, Chem. Biol. Interact. 178 (2009) 99-109.
7. L. Skarydova, A. Skarka, R. Novotna, L. Zivna, H.J. Martin, V. Wsol, E. Maser, Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin, Toxicology 264 (2009) 52-60.
8. H. Cortes-Funes, C. Coronado, Role of anthracyclines in the era of targeted therapy, Cardiovasc. Toxicol. 7 (2007) 56-60.
9. T. Simunek, M. Sterba, O. Popelova, M. Adamcova, R. Hrdina, V. Gersl, Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol. Rep. 61 (2009) 154-171.
10. L.E. Olson, D. Bedja, S.J. Alvey, A.J. Cardounel, K.L. Gabrielson, R.H. Reeves, Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1, Cancer Res. 63 (2003) 6602-6606. (Pubitemid 37336434)
11. G.L. Forrest, B. Gonzalez, W. Tseng, X. Li, J. Mann, Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice, Cancer Res. 60 (2000) 5158-5164.
12. R.D. Olson, P.S. Mushlin, D.E. Brenner, S. Fleischer, B.J. Cusack, B.K. Chang, R.J. Boucek Jr., Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol, Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 3585-3589.
13. A Mordente, G. Minotti, G.E. Martorana, A. Silvestrini, B. Giardina, E. Meucci, Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications, Biochem. Pharmacol. 66 (2003) 989-998.
14. P. Borchmann, K. Hubel, R. Schnell, A. Engert, Idarubicin: a brief overview on pharmacology and clinical use, Int. J. Clin. Pharmacol. Ther. 35 (1997) 80-83. (Pubitemid 27081326)
15. M. Joerger, A.D. Huitema, P.L. Meenhorst, J.H. Schellens, J.H. Beijnen, Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma, Cancer Chemother. Pharmacol. 55 (2005) 488-496.
16. O.S. Bains, M.J. Karkling, J.M. Lubieniecka, T.A. Grigliatti, R.E. Reid, K.W. Riggs, Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism, J. Pharmacol. Exp. Ther. (2009).
17. O.S. Bains, M.J. Karkling, T.A. Grigliatti, R.E. Reid, K.W. Riggs, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin, Drug Metab. Dispos. 37 (2009) 1107-1114.
18. N. Kassner, K. Huse, H.J. Martin, U. Godtel-Armbrust, A. Metzger, I. Meineke, J. Brockmoller, K. Klein, U.M. Zanger, E. Maser, L. Wojnowski, Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver, Drug Metab. Dispos. 36 (2008) 2113-2120.
19. J.G. Blanco, W.M. Leisenring, V.M. Gonzalez-Covarrubias, T.I. Kawashima, S.M. Davies, M.V. Relling, L.L. Robison, C.A. Sklar, M. Stovall, S. Bhatia, Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer, Cancer 112 (2008) 2789-2795. (Pubitemid 351969225)
20. O.S. Bains, R.H. Takahashi, T.A. Pfeifer, T.A. Grigliatti, R.E. Reid, K.W. Riggs, Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin, Drug Metab. Dispos. 36 (2008) 904-910.
21. R. Novotna, V. Wsol, G. Xiong, E. Maser, Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3, Toxicol. Lett. 181 (2008) 1-6.
22. H. Ohara, Y. Miyabe, Y. Deyashiki, K. Matsuura, A. Hara, Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver, Biochem. Pharmacol. 50 (1995) 221-227.
23. E.S Pilka, F.H. Niesen, W.H. Lee, Y. El-Hawari, J.E. Dunford, G. Kochan, V. Wsol, H.J. Martin, E. Maser, U. Oppermann, Structural basis for substrate specificity in human monomeric carbonyl reductases, PLoS One. 4 (2009) e7113.
24. H.J. Martin, U. Breyer-Pfaff, V. Wsol, S. Venz, S. Block, E. Maser, Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics, Drug Metab. Dispos. 34 (2006) 464-470.
25. R.H. Takahashi, O.S. Bains, T.A. Pfeifer, T.A. Grigliatti, R.E. Reid, K.W. Riggs, Aldoketo reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro, Drug Metab. Dispos. 36 (2008) 991-994.
26. M. Soldan, K.J. Netter, E. Maser, Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells, Biochem. Pharmacol. 51 (1996) 117-123.
27. W. Ax, M. Soldan, L. Koch, E. Maser, Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction, Biochem. Pharmacol. 59 (2000) 293-300.
28. M. Gavelova, J. Hladikova, L. Vildova, R. Novotna, J. Vondracek, P. Krcmar, M. Machala, L. Skalova, Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells, Chem. Biol. Interact. 176 (2008) 9-18.
29. D. Crivellari, D. Lombardi, S. Spazzapan, A. Veronesi, G. Toffoli, New oral drugs in older patients: a review of idarubicin in elderly patients, Crit. Rev. Oncol. Hematol. 49 (2004) 153-163. (Pubitemid 38175441)
30. T. Yamashita, T. Fukushima, T. Ueda, Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes, Leuk. Lymphoma 49 (2008) 809-814. (Pubitemid 351517228)
31. S. Licata, A. Saponiero, A. Mordente, G. Minotti, Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction, Chem. Res. Toxicol. 13 (2000) 414-420. (Pubitemid 30327162)
32. E.N. Dessypris, D.E. Brenner, M.R. Baer, K.R. Hande, Uptake and intracellular distribution of doxorubicin metabolites in B-lymphocytes of chronic lymphocytic leukemia, Cancer Res. 48 (1988) 503-506. (Pubitemid 18056511)
33. N. Niitsu, T. Kasukabe, A. Yokoyama, J. Okabe-Kado, Y. Yamamoto-Yamaguchi, M. Umeda, Y. Honma, Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity, Mol. Pharmacol. 58 (2000) 27-36.
34. H. Loveless, E. Arena, R.L. Felsted, N.R. Bachur, Comparative mammalian metabolism of adriamycin and daunorubicin, Cancer Res. 38 (1978) 593-598. (Pubitemid 8311400)
35. Y. Watanabe, H. Nakai, H. Hoshiai, The effect of granisetron on in vitro metabolism of doxorubicin, irinotecan and etoposide, Curr. Med. Res. Opin. 21 (2005) 363-368.
36. K.E Maudens, C.P. Stove, W.E. Lambert, Optimization of a liquid chromatographic separation for the simultaneous determination of four anthracyclines and their respective 13-S-dihydro metabolites, J. Sep. Sci. 31 (2008) 1042-1049.
37. C.D. Georgiou, K. Grintzalis, G. Zervoudakis, I. Papapostolou, Mechanism of Coomassie brilliant blue G-250 binding to proteins: a hydrophobic assay for nanogram quantities of proteins, Anal. Bioanal. Chem. 391 (2008) 391-403.
38. A. Bogason, H. Bhuiyan, M. Masquelier, C. Paul, A. Gruber, S. Vitols, Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response, Eur. J. Clin. Pharmacol. 65 (2009) 1179-1186.
39. C. Muller, E. Chatelut, V. Gualano, F.M. De, F. Huguet, M. Attal, P. Canal, G. Laurent, Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion, Cancer Chemother. Pharmacol. 32 (1993) 379-384.
40. V. Wsol, B. Szotakova, L. Skalova, E. Maser, The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1, Toxicology 197 (2004) 253-261. (Pubitemid 38368118)